Drugs / OPS-2071
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01925521 | Aug 2013 → Apr 2014 | — | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05923892 | Aug 2023 → Aug 2024 | irritable bowel syndrome | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03850509 | Feb → May 2020 | Crohn disease | Otsuka Pharmaceutical Development & Commercialization, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02473393 | Aug 2015 → Mar 2017 | enteritis | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPS-2071 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01925521 ↗ |
| Modality | Small molecule | “OPS-2071 belongs to the fluoroquinolone family of compounds” NCT03850509 ↗ |
| Route | Oral | “single oral dose under fasted condition” NCT01925521 ↗ |